NCT01908777View on ClinicalTrials.gov

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 16, 2013

Primary Completion Date

October 3, 2025

Study Completion Date

October 3, 2025

Conditions
T Cell Non-Hodgkin Lymphoma
Interventions
OTHER

High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Trial Locations (10)

10604

Memorial Sloan Kettering Westchester, Harrison

11065

Memorial Sloan Kettering Cancer Center, New York

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

33612

Moffitt Cancer Center, Tampa

98109

Fred Hutchinson Cancer Research Center (Data Collection Only), Seattle

University of Washington (Data Collection Only), Seattle

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

Weill Cornell Medical Center, New York

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01908777 - A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter